LAVA Therapeutics NV

NASDAQ:LVTX  
3.78
+0.15 (+4.13%)
7:30:43 PM EDT: $3.63 -0.15 (-3.97%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)101.54M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$1.2 Million
Adjusted EPS-$0.60
See more estimates
10-Day MA$3.58
50-Day MA$4.31
200-Day MA$3.57
See more pivots

LAVA Therapeutics NV Stock, NASDAQ:LVTX

Yalelaan 60, Utrecht, Noord-Brabant 3584 CM
Netherlands
Phone: +31.63.000.30.35
Number of Employees: 58

Description

LAVA Therapeutics NV operates as an immuno-oncology company. It utilizing its proprietary Gammabody platform to develop a portfolio of bispecific gamma delta T cell engagers for the potential treatment of solid tumors and hematological malignancies. The company was founded by Erik van den Berg in 2016 and is headquartered in Utrecht, the Netherlands.